Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Krystal Biotech (KRYS – Research Report) today. The company’s shares closed last Friday at $48.72.
According to TipRanks.com, Livshits is a top 100 analyst with an average return of 69.4% and a 58.4% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Adverum Biotechnologies, Crispr Therapeutics AG, and Rocket Pharmaceuticals.
Currently, the analyst consensus on Krystal Biotech is a Strong Buy with an average price target of $96.67, representing a 97.9% upside. In a report issued on October 12, William Blair also maintained a Buy rating on the stock.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $87.29 and a one-year low of $40.04. Currently, Krystal Biotech has an average volume of 116.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments. The company was founded by Suma M. Krishnan in December 2017 and is headquartered in Pittsburgh, PA.
Read More on KRYS:
